Meet our Team
The Leadership Team
Matt Langevin
COO
Matt Langevin is COO of Sword Bio. Prior to Sword Bio, Matt was a Co-Founder of Bioagilytix Labs. Matt set the culture at Bioagilytix by making sure there was a science, client and patient first approach.
He has over 25 years of bench top experience involving assay development, qualification, validation and sample analysis in non-regulated and GLP environments.
David Osband
EVP, Sales and Marketing
David Osband is EVP, Sales and Marketing at Sword Bio. Prior to Sword Bio, David was an owner of Cambridge Biomedical. For the last 13 years David has been involved in successfully growing and operating
diagnostic and contract research laboratory businesses. David’s focus is always on finding a way to offer a superior level of quality, science and service to the market than what currently exists. Always understanding that at the end of the day the employees, clients and patients are all connected.
John Pirro
Director, Scientific Solutions
John joins Sword with a proven track record in the contract research space providing scientific insight, guidance, and consultation. Most recently, he was senior scientific advisor for KCAS in their bioanalytical
and biomarker group. In this position John oversaw the operations of bioanalytical analysis for immunological assays (ADA, Nab, etc.) as well as LBA analysis for ADCs, PEG-Proteins and mAb. John has experience working in both the pre-clinical and clinical space, which has helped clients significantly. John also has experience as a lead scientist with two major Pharmaceutical companies and is co-inventor on a number of patents.
David Dingott
CEO and Founder, Sword Bio
Mr. Dingott is a Fortune-10 trained business leader with 30 years’ experience identifying, creating and leading businesses from proof of concept to successful commercial enterprise. To help navigate Sword
toward success, Mr. Dingott has cultivated relationships with an elite network of industry leaders with strategic insight and extensive corporate relationship connections. In addition, Mr. Dingott serves on the board of directors of Cearna, Inc, which sells a unique gel based patch that dramatically reduces pain, swelling and bruising that is the result of trauma or surgical procedures.
Kara Harrison
Vice President, Quality Assurance
Kara joins Sword with a proven record of leading and scaling quality management programs and initiatives. Most recently, she was VP, Global Quality for BioAgilytix Labs. In this position Kara led a globally dispersed
team of quality professionals, working to standardize procedures and quality systems across distinct sites, delineating best practices, and collaborating with clients and colleagues at all levels to enhance quality. Kara puts an emphasis on expanding business capabilities and driving operational success in the contract research space, providing quality oversight, implementation, and consultation regarding Quality Assurance and Regulatory Compliance.
The Board of Directors
Gail S. Page
Chair
Ms. Page is a diagnostics industry veteran with over 25 years executive experience, including commercialization, business development and general management of leading companies who are among Sword’s target customers. In January 2013
Ms. Page founded Vineyard Investment Advisors. VIA is focused on partnering with entrepreneurs, businesses, and universities to transform their ideas into products and services. Prior to this venture, Ms. Page served as the President / CEO of Vermillion, Inc. from Jan 2006 thru December 2012. She was a member of the board from 2006 thru 2012 and served as Chairperson from 2010-2011. Vermillion is a healthcare company focused on developing and commercializing novel diagnostic blood test. Upon joining Vermillion in 2004 she inspired a pioneering spirit. Under her leadership the company was repositioned to embrace the progressive nature of its pipeline, successfully raised over $100M in funding, developed and commercially launched the first FDA-cleared blood test to help diagnose ovarian cancer. Ms. Page has spent her entire career in health care and has a passion for emerging technologies that advance the efforts in personalized medicine.
Mel Schatz
Board Member
Mr. Schatz has 30 years of leadership experience in healthcare and senior management postions in diagnostics and devices with companies including Marion Laboratories, Medtronic, Bacchus Labs and Abbott Labs. Mr. Schatz’s experience with
Abbott Labs included worldwide management of the Cancer Business Unit headquartered in the U.S. and Director of Marketing for Dainabot, Abbott joint venture in Japan. After fulfilling both of these roles subsequently, Mr. Schatz was promoted to Vice President of Abbott Diagnostics, Asia Pacific and President of Dainabot (combined diagnostic/pharmaceutical entity in Japan). Mr. Schatz also held positions as Vice President and Sector Manager, for Abbott’s benchtop analyzers and physician office diagnostics.
This experience has provided Mr. Schatz with a wide variety of skills including extensive international experience and Expertise with healthcare specialists and investors to define business opportunities.
V. Edward Grogg
Board Member
V. Edward Grogg is the President/CEO and Founder of Carmel, Indiana based Ellipsis Ventures, LLC. Ellipsis Ventures is an investment company specializing in senior care real estate and health care technology companies that are laser focused on
differentiating themselves within their respective markets. Ellipsis partners with companies to assist them in bringing the necessary capital for the expansion of their products as well as to assist them in achieving their overall growth plans.
Prior to Ellipsis, Mr. Grogg was the President/Principal of Carmel, Indiana based Mainstreet Property Group, the largest developer of Next Generation™ Skilled Nursing & Short Term Rehabilitation properties in North America. With 35+ years of experience in the senior living field, Mr. Grogg’s background in leadership and management oversight allowed him to be actively involved in all aspects of the company’s growth including acquisitions, new development and operator relationships. During his tenure at Mainstreet, the company grew from ~$25,000,000 in assets to ~$1,000,000,000 in assets over the 7 year period. Also during this period, the company launched a successful IPO on the Toronto Stock Exchange under HealthLease Properties REIT on June 20, 2012. HealthLease was later sold to Health Care REIT (HCN) in November 2014. Mr. Grogg joined Mainstreet in May 2007 as a partner and sold his interests in June 2014.